Terbinafine Dosing for Adult Dermatophyte Onychomycosis
For adult dermatophyte onychomycosis, prescribe terbinafine 250 mg once daily for 6 weeks for fingernail infections and 12-16 weeks for toenail infections 1, 2.
Dosing Algorithm
Standard Adult Dosing (Strength of Recommendation A)
- Fingernail onychomycosis: 250 mg once daily × 6 weeks
- Toenail onychomycosis: 250 mg once daily × 12-16 weeks (most commonly 12 weeks)
This represents the FDA-approved dosing and is supported by the highest quality guideline evidence from the British Association of Dermatologists 1.
Pediatric Dosing (Age 1-12 years)
Weight-based dosing 1:
- <20 kg: 62.5 mg daily
- 20-40 kg: 125 mg daily
- >40 kg: 250 mg daily
Duration: 6 weeks for fingernails, 12 weeks for toenails
Important caveat: Terbinafine is unlicensed for pediatric use, requiring baseline liver function tests and complete blood count 1.
Why This Dose?
The British Association of Dermatologists guidelines give terbinafine a Grade A recommendation as first-line treatment for dermatophyte onychomycosis, explicitly stating it is "generally preferred over itraconazole" 1. This preference is based on superior efficacy demonstrated in multiple high-quality trials. The L.I.ON. study showed mycological cure rates of 76% with terbinafine versus 38% with itraconazole at 72 weeks, with complete cure rates approximately twice as high 3.
Pulse Dosing: Not Recommended
While pulse dosing regimens exist for itraconazole, continuous daily dosing is the established standard for terbinafine. Recent evidence actually contradicts pulse terbinafine approaches:
- A 2023 study found continuous terbinafine (250 mg daily × 12 weeks) achieved 76.67% clinical cure versus only 26.67% with pulse dosing (250 mg twice daily × 1 week every 4 weeks) 4
- The FDA label and all major guidelines specify continuous daily dosing only 2
Higher Doses: No Additional Benefit
Do not increase to 500 mg daily for onychomycosis. A 2023 study in tinea corporis/cruris found no significant difference between 250 mg and 500 mg doses, with overall poor cure rates for both 5. The 500 mg dose is not FDA-approved for onychomycosis and lacks supporting evidence for improved efficacy in nail infections.
Critical Monitoring Requirements
Before initiating treatment 1, 2:
- Baseline liver function tests (ALT, AST)
- Complete blood count
- Confirm diagnosis with KOH preparation and/or fungal culture
During treatment, monitor for:
- Hepatotoxicity symptoms (nausea, anorexia, fatigue, jaundice, dark urine)
- Taste disturbance (can be permanent—warn patients explicitly)
- Smell disturbance (can be permanent)
- Neutropenia (discontinue if neutrophil count ≤1,000 cells/mm³)
- Severe skin reactions (Stevens-Johnson syndrome, TEN)
Contraindications and Cautions
- History of allergic reaction to oral terbinafine
- Active or chronic liver disease
Use with caution in 1:
- Hepatic impairment
- Renal impairment
- Patients with psoriasis (can aggravate)
- Lupus (can cause subacute lupus-like syndrome)
When to Reassess
Re-evaluate patients 3-6 months after treatment initiation 1. The optimal clinical effect occurs months after mycological cure due to the time required for healthy nail outgrowth 2. At 5-year follow-up, terbinafine maintained superior outcomes with relapse rates of 23% versus 53% for itraconazole 3.
Common Pitfalls
Stopping too early: Patients may not see visible improvement during treatment—this is normal. Healthy nail must grow out over months.
Not warning about taste disturbance: This can be severe and permanent. Document that you warned the patient 2.
Forgetting baseline labs: Hepatotoxicity, though rare (0.04% serious adverse events), can be severe and requires baseline assessment 1.
Using in non-dermatophyte infections: Terbinafine has variable activity against yeasts and non-dermatophyte molds. For Candida onychomycosis, consider itraconazole or fluconazole instead 1.